Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Curcumin Also Inhibits Metastasis from Prostate Cancer

By BiotechDaily International staff writers
Posted on 23 Oct 2012
Researchers have now shown that curcumin, the key medicinal ingredient of turmeric, can also inhibit formation of metastases from prostate cancer, and have identified the main mechanism by which it does so.


Powdered turmeric has long been used in traditional medicine to treat osteoarthritis and other illnesses. Studies have shown that its active ingredient, the polyphenol curcumin, inhibits inflammatory reactions. A research team led by PD Dr. Beatrice Bachmeier of the Ludwig-Maximilians-University Munich (Munich, Germany) has been studying the effectiveness and the mode of action of curmumin in inhibition of cancer metastasis. In a previous study, Dr. Bachmeier and colleagues had demonstrated that the substance reduces statistically significantly the formation of lung metastases in an animal model of advanced breast cancer.


Prostate cancer is often diagnosed only after metastatic tumors have formed in other organs and emerging evidence suggests that chronic inflammation is a major risk factor for the development and metastatic progression of prostate cancer. The new study, published early online October 5, 2012, in the journal Carcinogenesis, was designed to investigate the efficacy of curcumin in preventing prostate cancer metastases and to determine its mechanism of action. The researchers first examined the molecular processes that are abnormally regulated in the carcinoma cells. Prostate and breast cancers are often associated with latent or chronic inflammatory reactions and, in both cases, the tumor cells were found to abnormally produce proinflammatory immunomodulators including the cytokines CXCL1 und CXCL2. They then observed that, among other inhibiting effects, curcumin specifically decreased the expression of these two proteins and other important metastasis-promoting factors. Furthermore, in a mouse model this effect was correlated with a decline in the incidence of metastases.


Since curcumin is well tolerated, it could be suitable for use in reducing metastatic potential by chemoprevention - for prophylactic use (primary prevention) and/or for the suppression of metastases where an established tumor is already present (secondary prevention). “This does not mean that the compound should be seen as a replacement for conventional therapies. However, it could play a positive role in [prevention or treatment]. In this context the fact that the substance is well tolerated is very important,” said Dr. Bachmeier.


A daily intake of up to 8 g of curcumin is regarded as safe, and its anti-inflammatory properties have long been exploited in traditional medicine. For prophylaxis, men with benign hyperplasia of the prostate (BHP) are one possible target group, as are women with a family history of breast cancer. The agent might also be valuable as a supplement to certain cancer therapies. Since curcumin’s beneficial effects must first be examined in controlled clinical tests, Dr. Bachmeier and colleagues are presently planning a clinical trial in patients suffering from therapy-resistant prostate carcinoma.

Related Links:

Ludwig-Maximilians-University Munich




Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.